Catyalyst Pharma (CPRX) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Corporate Update
May 10, 2016 4:56 PM EDTCORAL GABLES, Fla., May 10, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2016.
This past quarter has been very challenging, as we were very disappointed by the receipt of the refusal to file letter from the U.S. Food and Drug Administration (FDA) for the Firdapse® new drug application (NDA), said Patrick J. McEnany, Chief Executive Officer of Catalyst. While we are frustrated by... More
